BACKGROUND: Osteopontin (OPN) is an extracellular matrix glycoprotein that plays a role in a variety of cellular activities associated with inflammatory and fibrotic responses. Increased OPN levels in myocardium and plasma have been demonstrated in patients with dilated cardiomyopathy (DCM). However, nothing is known about OPN levels in patients with hypertrophic cardiomyopathy (HCM). Therefore, the aim of our study was to compare plasma OPN levels in patients with these two most common cardiomyopathies. PATIENTS AND METHODS: We examined plasma OPN as well as creatinine, C‑reactive protein (CRP), brain-type natriuretic peptide (BNP), and troponin I levels in 64 patients with DCM, 43 patients with HCM, and 75 control subjects. Transthoracic echocardiography was also performed on all cardiomyopathy patients. RESULTS: Plasma OPN levels were significantly elevated in patients with DCM compared with HCM patients (95 ± 43 vs. 57 ± 21 ng/ml; p < 0.001) and control subjects (54 ± 19 ng/ml; p < 0.001); however, there was no difference between HCM patients and control subjects. New York Heart Association (NYHA) class III or IV disease was more frequently present in DCM patients than in HCM subjects (44 % vs. 2 %, p < 0.0001). In multivariate analysis, BNP and CRP levels together with NYHA class were found to be significant predictors of plasma OPN levels in DCM patients (p = 0.002, p = 0.029, and p < 0.001 for BNP, CRP, and NYHA, respectively). CONCLUSION: Plasma OPN levels were associated with overall heart failure severity rather than with specific cardiomyopathy subtype in patients suffering from DCM or HCM, respectively.

2nd Department of Medicine Department of Cardiovascular Medicine 1st Faculty of Medicine Charles University and General University Hospital Prague U Nemocnice 2 128 08 Prague Czech Republic

Institute of Medical Biochemistry and Laboratory Diagnostics 1st Faculty of Medicine Charles University and General University Hospital Prague Prague Czech Republic

See more in PubMed

Hypertension. 1999 Feb;33(2):663-70 PubMed

QJM. 2002 Jan;95(1):3-13 PubMed

Eur J Heart Fail. 2002 Mar;4(2):139-46 PubMed

J Clin Invest. 2003 Jul;112(2):147-9 PubMed

Heart. 2004 Apr;90(4):464-70 PubMed

Hypertension. 2004 Dec;44(6):809-10 PubMed

Eur J Heart Fail. 2005 Aug;7(5):755-62 PubMed

Circulation. 2005 Sep 6;112(10):1428-34 PubMed

J Vet Med Sci. 2006 Apr;68(4):379-82 PubMed

Heart Fail Rev. 2006 Mar;11(1):83-92 PubMed

Heart. 2006 Oct;92(10):1514-5 PubMed

Eur Heart J. 2008 Jan;29(2):270-6 PubMed

Comp Med. 2007 Dec;57(6):546-53 PubMed

J Am Coll Cardiol. 2008 Apr 8;51(14):1384-92 PubMed

Mol Cell Biochem. 2009 Feb;322(1-2):25-36 PubMed

Circ Res. 2009 Apr 10;104(7):851-9 PubMed

Eur J Echocardiogr. 2009 Mar;10(2):165-93 PubMed

Ann Intern Med. 2009 May 5;150(9):604-12 PubMed

J Mol Cell Cardiol. 2010 Mar;48(3):538-43 PubMed

Circ Heart Fail. 2008 May;1(1):43-9 PubMed

Heart Fail Rev. 2010 Sep;15(5):487-94 PubMed

Circ Heart Fail. 2010 May;3(3):431-9 PubMed

Semin Thromb Hemost. 2010 Mar;36(2):195-202 PubMed

J Am Soc Echocardiogr. 2010 Jul;23(7):685-713; quiz 786-8 PubMed

Int J Cardiol. 2011 Dec 15;153(3):306-10 PubMed

Immunol Res. 2011 Apr;49(1-3):160-72 PubMed

Fa Yi Xue Za Zhi. 2012 Aug;28(4):247-51 PubMed

Eur J Heart Fail. 2013 Dec;15(12):1390-400 PubMed

Eur Heart J. 2014 Oct 14;35(39):2733-79 PubMed

Life Sci. 2014 Nov 18;118(1):1-6 PubMed

Eur Heart J Cardiovasc Imaging. 2015 Mar;16(3):233-70 PubMed

Circ Res. 2016 Jun 24;119(1):159-76 PubMed

Am J Cardiol. 1986 Feb 15;57(6):450-8 PubMed

Proc Natl Acad Sci U S A. 1986 Dec;83(23):8819-23 PubMed

J Immunol. 1999 Jan 15;162(2):1024-31 PubMed

Osteopontin: The Molecular Bridge between Fat and Cardiac-Renal Disorders